Lanchi Ventures Leads $42M Series A Financing for Allink Biotherapeutics to Accelerate Global Development of Bispecific Antibody and ADC Pipeline

Lanchi Ventures Leads $42M Series A Financing for Allink Biotherapeutics to Accelerate Global Development of Bispecific Antibody and ADC Pipeline

The series A investment round secures resources for advancing global Phase I/II clinical programs and orchestrating the company's global footprint expansion. BEIJING, Nov. 28, 2024 /PRNewswire/ -- Allink Biotherapeutics, a clinical-stage...

Allink Biotherapeutics Raises $42M Series A Financing to Accelerate Global Development of Bispecific Antibody and ADC Pipeline

Allink Biotherapeutics Raises $42M Series A Financing to Accelerate Global Development of Bispecific Antibody and ADC Pipeline

The series A investment round secures resources for advancing global Phase I/II clinical programs and orchestrating the company's global footprint expansion. SHANGHAI, Nov. 28, 2024 /PRNewswire/ -- Allink Biotherapeutics, a clinical-stage...

menu
menu